Cometta A, Baumgartner J D
Division des maladies infectieuses, CHUV, Lausanne.
Schweiz Med Wochenschr Suppl. 1996;76:28S-33S.
Until recently, aminoglycoside antibiotics were the cornerstone for the treatment of severe infections. The rationale for using combination therapy containing beta-lactams and aminoglycosides was not only to broaden the antimicrobial spectrum but also to achieve enhanced bacterial killing by synergism and to prevent the emergence of antibiotic resistance. However, with the advent of new potent broad-spectrum and highly bactericidal antibiotics, the necessity of combining beta-lactams with aminoglycosides should be reassessed. This review questions the use of aminoglycosides in three severe infections frequently observed in intensive care units, nosocomial pneumonia, nosocomial sepsis and severe diffuse peritonitis. A review of the literature suggests that the addition of an aminoglycoside to a broad-spectrum beta-lactam does not improve the outcome in nosocomial pneumonia and severe diffuse peritonitis. However, the lack of large prospective studies in severe sepsis or septic shock makes it impossible to draw any conclusion about the addition of an aminoglycoside, and the administration of these agents must be decided on an individual basis.
直到最近,氨基糖苷类抗生素仍是治疗严重感染的基石。使用包含β-内酰胺类和氨基糖苷类的联合疗法的基本原理不仅是为了拓宽抗菌谱,还为了通过协同作用增强细菌杀灭效果并防止抗生素耐药性的出现。然而,随着新型强效广谱和高杀菌性抗生素的出现,应重新评估将β-内酰胺类与氨基糖苷类联合使用的必要性。本综述对重症监护病房中常见的三种严重感染(医院获得性肺炎、医院获得性败血症和严重弥漫性腹膜炎)中氨基糖苷类抗生素的使用提出质疑。文献综述表明,在广谱β-内酰胺类药物中添加氨基糖苷类并不能改善医院获得性肺炎和严重弥漫性腹膜炎的治疗结果。然而,由于缺乏关于严重脓毒症或脓毒性休克的大型前瞻性研究,无法就添加氨基糖苷类药物得出任何结论,这些药物的使用必须根据个体情况决定。